REGENEREX PHARMA, INC.: 10-Q filed 2014-07-16
What REGENEREX PHARMA, INC. reported in its quarterly report filed 2014-07-16 (fiscal Q2 2014): 15 published measures, 45 facts as tagged in accession 0001072588-14-000066.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-07-16
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001072588-14-000066 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | 5,849 | USD | |
| At 2013-11-30 | 50,990 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | 699,328 | USD | |
| At 2013-11-30 | 1,751,122 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | -693,479 | USD | |
| At 2013-11-30 | -1,700,132 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | 1,683 | USD | |
| At 2013-11-30 | 157 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | 1,143,370 | USD | 93 |
| 2013-12-01 to 2014-05-31 | 971,653 | USD | 182 |
| 2010-06-26 to 2014-05-31 | -922,044 | USD | 1436 |
| 2013-02-28 to 2013-05-31 | -248,074 | USD | 93 |
| 2012-12-01 to 2013-05-31 | -492,438 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | -32,185 | USD | 93 |
| 2013-12-01 to 2014-05-31 | -41,474 | USD | 182 |
| 2010-06-26 to 2014-05-31 | -251,134 | USD | 1436 |
| 2013-02-28 to 2013-05-31 | -24,411 | USD | 93 |
| 2012-12-01 to 2013-05-31 | -27,411 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | 33,000 | USD | 93 |
| 2013-12-01 to 2014-05-31 | 43,000 | USD | 182 |
| 2010-06-26 to 2014-05-31 | 258,614 | USD | 1436 |
| 2013-02-28 to 2013-05-31 | 20,000 | USD | 93 |
| 2012-12-01 to 2013-05-31 | 20,000 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-06-26 to 2014-05-31 | -10,000 | USD | 1436 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | -105,837 | USD | |
| At 2013-11-30 | -105,837 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | 151,152,341 | shares | 93 |
| 2013-12-01 to 2014-05-31 | 151,143,249 | shares | 182 |
| 2013-02-28 to 2013-05-31 | 149,858,439 | shares | 93 |
| 2012-12-01 to 2013-05-31 | 149,470,376 | shares | 182 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | -713 | USD | 93 |
| 2013-12-01 to 2014-05-31 | -1,599 | USD | 182 |
| 2010-06-26 to 2014-05-31 | -9,351 | USD | 1436 |
| 2013-02-28 to 2013-05-31 | -885 | USD | 93 |
| 2012-12-01 to 2013-05-31 | -1,812 | USD | 182 |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-11-30 | 45,000 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | 151,158,000 | shares | |
| At 2013-11-30 | 151,123,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-05-31 | 183,244 | USD | |
| At 2013-11-30 | 148,279 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-28 to 2014-05-31 | 8,308 | USD | 93 |
| 2013-12-01 to 2014-05-31 | 11,378 | USD | 182 |
| 2010-06-26 to 2014-05-31 | 64,403 | USD | 1436 |
| 2013-02-28 to 2013-05-31 | 6,605 | USD | 93 |
| 2012-12-01 to 2013-05-31 | 8,545 | USD | 182 |
Inspect the source
- Entity
- REGENEREX PHARMA, INC. / CIK 0001357878
- Captured
- 2026-09-21T17:18:44.819Z
- SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))